Key Points
- Martine Rothblatt sold 4,000 United Therapeutics shares on Dec. 3 at an average price of $475.27 for proceeds of $1,901,080, leaving her with 130 shares — a reported 96.85% decline in direct ownership.
- United Therapeutics beat EPS expectations with $7.16 for the quarter (revenue $799.5M slightly below estimates) and showed strong profitability metrics, including a 40.65% net margin and 18.83% ROE.
- The stock trades near recent highs (opened $489.31; 1‑year high $492.62), has a market cap of $21.07 billion, and holds a MarketBeat consensus of "Moderate Buy" with a $505 average price target.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $475.27, for a total value of $1,901,080.00. Following the completion of the sale, the chief executive officer directly owned 130 shares of the company's stock, valued at $61,785.10. This represents a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Stock Performance
NASDAQ:UTHR opened at $489.31 on Friday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $492.62. The stock has a fifty day moving average price of $452.91 and a two-hundred day moving average price of $367.90. The stock has a market capitalization of $21.07 billion, a price-to-earnings ratio of 18.54, a PEG ratio of 4.81 and a beta of 0.86.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping the consensus estimate of $6.89 by $0.27. The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business's revenue was up 6.8% on a year-over-year basis. During the same period in the previous year, the firm earned $6.39 EPS. On average, analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.
Institutional Investors Weigh In On United Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB increased its position in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after buying an additional 49 shares in the last quarter. Chung Wu Investment Group LLC purchased a new stake in shares of United Therapeutics in the second quarter valued at $29,000. Abich Financial Wealth Management LLC acquired a new stake in shares of United Therapeutics during the third quarter valued at $44,000. SVB Wealth LLC purchased a new stake in United Therapeutics during the 1st quarter worth about $32,000. Finally, WealthCollab LLC raised its stake in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.
Analyst Upgrades and Downgrades
UTHR has been the topic of several recent analyst reports. Weiss Ratings restated a "buy (b-)" rating on shares of United Therapeutics in a research report on Monday. HC Wainwright boosted their price target on United Therapeutics from $500.00 to $525.00 and gave the stock a "buy" rating in a research note on Thursday, October 30th. Morgan Stanley set a $447.00 price objective on United Therapeutics in a research note on Wednesday, October 29th. Jefferies Financial Group reiterated a "buy" rating and set a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th. Finally, Wells Fargo & Company upped their target price on United Therapeutics from $414.00 to $423.00 and gave the company an "equal weight" rating in a report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $505.00.
Get Our Latest Stock Report on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
